Ryvu Therapeutics SA’s share price is zł14.74. Its GF Value is zł46. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Ryvu Therapeutics SA stock is .
The GF Value represents the current intrinsic value of a stock derived from our proprietary algorithm. It is based primarily on the historical multiples of where the stocks have been traded and the future growth of the business, adjusted for the past returns and growth. The GF Value has been verified by backtesting and daily updated model portfolios.
In addition to considering the current valuation, the growth potential of a company's value is equally important. Companies with faster growth rates tend to increase their value more quickly. Therefore, it's essential to look at the Price-to-Future GF Value ratios as well. The results are shown below:
| Price: zł14.74 | GF Value | Price/GF Value | ||
|---|---|---|---|---|
| Current | zł46 | 0.32 | ||
| Next FY1 End | zł47.53 | 0.31 | ||
| Next 12 Month | zł50.16 | 0.29 | ||
| Next FY2 End | zł51.48 | 0.29 |
GuruFocus performed a correlation analysis comparing Ryvu Therapeutics SA's stock price with key financial metrics: revenue per share, book value per share, EPS without NRI, and operating cash flow per share.
The analysis reveals the strongest correlation between Ryvu Therapeutics SA's stock price and Earnings without NRI per share, with a coefficient of 85%. This is followed by a 76% correlation with Book Value per share. Ryvu Therapeutics SA’s stock price shows no significant correlation with Operating Cash Flow per share. Ryvu Therapeutics SA’s stock price shows no significant correlation with Revenue per share.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
